PT - JOURNAL ARTICLE AU - JOSHUA E. MUSCAT AU - ANNE-MARIE DYER AU - RAPHAEL E. ROSENBAUM AU - BASIL RIGAS TI - Nitric Oxide-releasing Medications and Colorectal Cancer Risk: The Framingham Study DP - 2005 Nov 01 TA - Anticancer Research PG - 4471--4474 VI - 25 IP - 6C 4099 - http://ar.iiarjournals.org/content/25/6C/4471.short 4100 - http://ar.iiarjournals.org/content/25/6C/4471.full SO - Anticancer Res2005 Nov 01; 25 AB - Background: The major sources of human exposure to nitric oxide (NO) are medicinal nitrovasodilators that release NO into the vasculature. Experimental NO-donating aspirin also releases NO in a similar manner, and is a potent in vitro inhibitor of colon cancer. Materials and Methods: The effects of nitrovasodilators on the risk of colorectal cancer was studied in the Framingham Heart and Offspring studies among 145 cases of colorectal cancer and 433 matched controls. Results: Eleven percent of controls reported currently using nitroglycerine or other long-lasting nitrates. In conditional logistic regression analysis, the odds ratio (OR) for colorectal cancer associated with nitrovasodilator use was 1.2 (95% confidence interval [CI] 0.6, 2.2). In subgroup analysis, the OR was 0.7 (95% CI 0.2, 2.2) in aspirin users and 1.6 (95% CI 0.8, 3.2) in subjects not taking aspirin. Conclusion: These data indicate that NO does not change the risk of colorectal cancer. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved